Splisense
Founded 2017 · 16 employees on LinkedIn · 1 known investors
SpliSense develops RNA-based therapies using antisense oligonucleotides (ASOs) to restore and modify protein function. The company targets the underlying cause of pulmonary diseases that currently lack treatment options.
Investors · 1
Frequently asked questions
- What does Splisense do?
- SpliSense develops RNA-based therapies using antisense oligonucleotides (ASOs) to restore and modify protein function. The company targets the underlying cause of pulmonary diseases that currently lack treatment options.
- Who are Splisense's investors?
- Splisense's investors include Israel Biotech Fund.